Grifols SA (GRLS)

11.350
-0.155(-1.35%)
  • Volume:
    242,359
  • Bid/Ask:
    11.285/11.415
  • Day's Range:
    11.330 - 11.525

GRLS Overview

Prev. Close
11.505
Day's Range
11.33-11.525
Revenue
6.36B
Open
11.49
52 wk Range
7.82-19.92
EPS
0.069
Volume
242,359
Market Cap
7.7B
Dividend (Yield)
0.426
(2.28%)
Average Volume (3m)
1,832,595
P/E Ratio
164.42
Beta
0.433
1-Year Change
-42.04%
Shares Outstanding
678,410,694
Next Earnings Date
Jul 26, 2023
What is your sentiment on Grifols?
or
Vote to see community's results!

Grifols SA Company Profile

Grifols SA Company Profile

Employees
26326
Market
Spain
  • Type:Equity
  • Market:Spain
  • ISIN:ES0171996087

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company’s products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellBuySell
Technical IndicatorsStrong SellStrong SellStrong SellStrong BuyStrong Sell
SummaryStrong SellStrong SellStrong SellStrong BuyStrong Sell